de la Torre REE, Aguilera PGR, Cutié AY, Argüelles GI

Language: Spanish
References: 22
Page: 396-411
PDF size: 558.13 Kb.

ABSTRACT

Introduction: optic neuritis is an inflammation of the optic nerve of varied etiology related to some conditions such as inflammatory processes and systemic diseases.
Objective: to describe structure and function in autoimmune inflammatory optic neuropathy.
Methods: a descriptive of a series of cases study at "Lucía Iñiguez Landín" Surgical Clinical Hospital in 2012 was done. The universe consisted of 18 patients with inflammatory optic neuropathy. The sample included 12 patients with autoimmune etiology. The patients were distributed according to etiological and topographical diagnosis. Funduscopy and confocal laser tomography were performed. Functional evaluation of the optic nerve was performed according to visual Evoked Potentials.
Results: demyelinating etiology and anterior topographic etiology predominated, of the eight patients of the topographic variety, seven had multiple sclerosis and one case was due to systemic lupus erythematosus. The posterior demyelinating variety was observed in two cases. The greatest number of patients presented increased thickness of the retinal nerve fiber layer as a result of funduscopy and confocal tomography. The results with laser tomography coincided with those obtained by funduscopy, the eight cases with anterior topography showed increased thickness of the retinal nerve fiber layer and the two cases of posterior topography showed a normal thickness. The greater number of patients presented increased latency and normal amplitude of the evoked potentials, the majority of cases presented increased latency (9 cases for 75.0%) and three showed a very increased latency (25.0%). The amplitude was normal in eight patients and in four it diminished. Of these (34%), two corresponded to anterior optic neuritis.
Conclusions: the relationship structure in the optic nerve damage in autoimmune inflammatory neuropathy was corroborated.

REFERENCES

1. Eguía Martínez F, Rió Torres M, Capote Cabrera A. Manual de Diagnóstico y Tratamiento en Oftalmología. La Habana: Ecimed; 2009.

2. Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, et al. Three years of experience: the Italian registry and safety data update. Neurol Sci. 2011[citado 25 feb 2015]; 31(Supl 3):295-297. Disponible en: http://link.springer.com/article/10.1007%2Fs10072-010-0356-8

3. Laria C, Alio J, Rodríguez JL, Sánchez J, Galal A. Neuritis óptica tras vacunación de meningitis. Arch Soc Esp Oftalmol. 2006[citado 6 mar 2015]; 81(8): 479-482. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16933172

4. Carruthers RL, Berger J. Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice. Mult Scler Relat Disord. 2014[citado 25 ago 2014]; 3(4):419-430. Disponible en: http://www.sciencedirect.com/science/article/pii/S221103481400008X

5. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010[citado 9 jul 2015]; 9(3):299-308. Disponible en: http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2810%2970007-7/

6. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. 2010[citado 25 may 2015]; 257(4):580-583. Disponible en: http://www.springerlink.com/content/18708885525273v4/

7. Aldinucci A, Biagioli T, Manuelli C, Repice AM, Massacesi L, Ballerini C. Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP.J Neuroimmunol. 2010[citado 29 sep 2014]; 218(1-2):28-35. Disponible en: http://www.jni-journal.com/article/S0165-5728%2809%2900435-4/

8. Malik A, Ahmed M, Golnik K. Treatment options for atypical optic neuritis. Indian J Ophthalmol. 2014 [citado 29 sep 2015]; 62(10):982-984. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278124/

9. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014[citado 25 may 2015]; 13(3):257-267. Disponible en: http://www.thelancet.com/pdfs/journals/laneur/PIIS1474-4422%2814%2970005-5.pdf

10. Talbott JF, Cao Q, Bertram J, Nkansah M, Benton RL, Lavik E, et al. CNTF promotes the survival and differentiation of adult spinal cord-derived oligodendrocyte precursor cells in vitro but fails to promote remyelination in vivo. Exp Neurol. 2007[citado 5 ago 2015]; 204(1):485-489. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430994/?tool=pubmed

11. Berg KT, Harrison AR, Lee MS. Perioperative visual loss in ocular and nonocular surgery. Clin Ophthalmol. 2010[citado 5 ago 2015]; 4:531-46. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893763

12. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008[citado 25 ago 2014]; 65(6):727-732. Disponible en: http://archneur.ama-assn.org/cgi/content/abstract/65/6/727

13. Roed HG, Langkilde A, Sellebjerg F, Lauritzen M, Bang P, Mørup A, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005[citado 25 ago 2014]; 64(5):804-810. Disponible en: http://www.neurology.org/content/64/5/804

14. Diem R, Hobom M, Maier K, Weissert R, Storch MK, Meyer R, et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci. 2003[citado 25 ago 2014]; 23(18):6993-7000. Disponible en: http://www.jneurosci.org/content/23/18/6993

15. Hedges TR, Vuong LN, González García AO, Mendoza CE, Amaro ML. Subretinal fluid from anterior ischemic optic neuropathy demonstrated by optical coherence tomography. Arch Ophthalmol. 2008[citado 25 mar 2015]; 126(6):812-815. Disponible en: http://archopht.jamanetwork.com/article.aspx?articleid=420558

16. Göbel W, Lieb WE, Grein HJ. Quantitative and objective follow-up of papilledema with the Heidelberg Retina Tomograph. Ophthalmologe. 1997[citado 25 ago 2015]; 94(9):673-677. Disponible en: http://link.springer.com/article/10.1007/s003470050182

17. Herráiz C, Hernández Calvín FJ, Plaza G, Toledano A, De los Santos G. Interacción multisensorial en el acufeno: evocación por movimientos oculares y estimulación somatosensorial. Acta Otorrinolaringol Española. 2003[citado 25 ago 2015]; 54(5): 329-336. www.elsevier.es/es-revista-acta-otorrinolaringologica-espanola-102-pdf-13097193-S300

18. Asselman P, Chadwick DW, Marsden CD. Visual evoked responses in the diagnosis and management of patients suspected of multiple sclerosis. Brain. 1975[citado 25 ago 2015]; 98: 261-282. Disponible en: http://brain.oxfordjournals.org/content/98/2/261.long

19. Zwibel HL. Treatment Study Principal Investigators. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand. 2006[citado 25 ago 2015]; 113:378-386. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0404.2006.00627.x/pdf

20. Johnson KP. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag. 2010[citado 25 ago 2015]; 6:153-172.Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857614/?tool=pubmed

21. Kopadze T, Döbert M, Leussink VI, Dehmel T, Kieseier BC. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol. 2009[citado 25 ago 2015]; 16(3):409-12. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1468-1331.2008.02433.x/full

22. Murphy JA, Harris JA, Crannage AJ. Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2010[citado 25 ago 2015]; 6(1): 619-624.Disponible en: http://www.dovepress.com/articles.php?article_id=5342